A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

NCT03997539 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

256

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Pyrotinib
DRUG: Treatment of physician's choice
DRUG: vinorelbine

Sponsor

Sun Yat-sen University

Collaborators

[object Object]